Related Experiment Videos
Troxacitabine activity in extramedullary myeloid leukemia
Yesid Alvarado1, Hagop M Kantarjian, Jorge E Cortes
1Department of Leukemia, M.D. Anderson Cancer Center, The University of Texas, Houston 77030, USA.
Hematology (Amsterdam, Netherlands)
|September 24, 2002
Summary
Troxacitabine demonstrates significant antileukemic activity in extramedullary myeloid leukemias. This novel nucleoside analog showed a 60% complete response rate in patients with refractory disease.
Area of Science:
- Oncology
- Pharmacology
- Hematology
Background:
- Troxacitabine is a novel L-enantiomer nucleoside analog with unique pharmacokinetic and resistance profiles.
- It exhibits significant activity in refractory myeloid leukemias, both as a single agent and in combination therapies.
Purpose of the Study:
- To evaluate the efficacy of troxacitabine-based regimens in patients with extramedullary myeloid leukemia.
- To assess the response rates and duration of remission in this patient population.
Main Methods:
- Phase 1 or 2 clinical studies involving 170 patients with refractory myeloid leukemia.
- Analysis of a subgroup of 10 patients with biopsy-proven extramedullary disease treated with troxacitabine or troxacitabine plus cytarabine.
Main Results:
- 60% (6 out of 10) of patients with extramedullary myeloid leukemia achieved a complete response with disappearance of extramedullary lesions.
- Responses included remissions of varying durations, with some patients experiencing relapse within 3 months.
Conclusions:
- Troxacitabine-based therapy shows significant antileukemic activity in extramedullary myeloid leukemias.
- Further investigation of troxacitabine in this specific clinical setting is warranted.